Novacyt will validate its Novaprep liquid-based cytology platform with Abbott's RealTime High Risk human papillomavirus assay.
The International Thyroid Congress and Annual Meeting of the American Thyroid Association announced studies validating diagnostics tests for several companies.
The company demonstrated high analytical sensitivity and specificity, and also showed clinical data supporting a high concordance with tumor tissue sequencing.
The partners will run several studies to validate the use of the MyPRS test in informing disease management in patients with multiple myeloma and its precursors.
The 3M Molecular Detection Assay 2 – Listeria monocytogenes is 30 percent faster than the first-generation test.
The company completed analytical validation of MetaSite Breast, and is planning to complete three additional studies before launching it on the market with MenaCalc.
Quest offers its BRCAvantage test on the MiSeq, has other oncology and neurology NGS tests in development, and is converting all its Sanger tests to NGS.
The test, called CANScript, combines an ex vivo tumor ecosystem with a machine learning algorithm to predict the therapeutic efficacy of cancer drugs.
Despite improvements to sequencing technology, there are still significant challenges in developing clinical NGS-based gene panels.
According to New Scientist, GEDmatch changed its terms and conditions over the weekend to opt its users out of law enforcement searches.
The Atlantic looks into time spent pursuing gene leads generated through candidate gene studies.
A twin study uncovers evidence that genes may influence whether someone gets a dog, Martha Stewart reports.
In PNAS this week: Cdx2 cells can help regenerate heart tissue in mice following a heart attack, PIWI-interacting small RNA levels in human cancer, and more.